Neurizon Therapeutics (ASX:NUZ) was told by the Australian Patent Office of the grant of a new method of use patent, which will extend protection for its NUZ-001 drug candidate and related compounds across key therapeutic areas, including mTOR-pathway related diseases, such as amyotrophic lateral sclerosis, and other neurodegenerative diseases, according to a Tuesday Australian bourse filing.

The granted patent complements Neurizon's existing US patent for NUZ-001 in neurodegenerative diseases and cancer and gives the firm unified intellectual property protection through to May 2041 across major global markets, per the filing.